Abstract
To evaluate the response to sub-Tenon's triamcinolone injection in patients with uveitis. We studied 28 eyes with macular edema associated with controlled uveitis. We administered sub-Tenon's injection of triamcinolone and followed the patients for 180 days to analyze the positive effects (improvement of macular edema and visual acuity) and monitor the possible adverse effects. This prospective study was conducted at the Department of Ophthalmology, Hospital de Clínicas de Porto Alegre, Brazil. We observed improvement in macular edema in 86% of patients. The mean central macular thickness at each time point of assessment was 432.22, 298.80, 286.37, 267.49, 253.87, and 253.49 mm at baseline (before sub-Tenon's injection of triamcinolone), 15 days after the procedure, at 30 days, at 60 days, at 90 days, and at 180 days, respectively. The mean reduction in retinal thickness was 30.8%, 33.7%, 38.11%, 41.2%, and 41.35% at 15, 30, 60, 90, and 180 days of follow-up, respectively. Visual acuity also improved in 85.7% of patients, with a mean improvement of 1.36, 1.93, 2.23, 2.26, and 2.30 lines gained on the Early Treatment Diabetic Retinopathy Study chart at 15, 30, 60, 90, and 180 days of follow-up, respectively. No statistically significant increases in intraocular pressure and conjunctival abnormalities were caused by the procedure, and no other adverse effects were observed. Overall, the results of this study were similar to those described in the literature. Sub-Tenon's injection of triamcinolone provides reduced macular thickness and improvement in visual acuity with no significant adverse effects and is therefore an effective and safe procedure for the treatment of sequelae of uveitis.
Highlights
The term “uveitis” refers to any intraocular inflammation affecting the uveal tract[1]
We studied 28 eyes with macular edema associated with controlled uveitis
Visual acuity improved in 85.7% of patients, with a mean improvement of 1.36, 1.93, 2.23, 2.26, and 2.30 lines gained on the Early Treatment Diabetic Retinopathy Study chart at 15, 30, 60, 90, and 180 days of follow-up, respectively
Summary
The term “uveitis” refers to any intraocular inflammation affecting the uveal tract[1]. Ocular involvement may lead to complications such as cataract, glaucoma, and macular edema-a late complication that, if left untreated for long, may result in irreversible visual loss[2,3]. This content is licensed under a Creative Commons Attributions 4.0 International License. Uveitis is treated mainly with corticosteroids[4,5]. This class of medication represents the first line of therapy in patients with non-infectious uveitis, and its effectiveness has stirred heated debate at uveitis treatment centers[6,7,8]. Few have assessed its role in uveitis-related cases
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have